Caribou Biosciences, Inc.

Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing allogeneic, or off-the-shelf, cell therapies for cancer. Its core platform is chRDNA (CRISPR hybrid RNA-DNA) genome-editing technology, which the company uses to engineer more precise cell therapies and to improve activity through approaches such as checkpoint disruption and immune cloaking. The company’s lead programs are vispa-cel (formerly CB-010), an anti-CD19 CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma. Caribou is still in the development stage and currently generates revenue from licensing and collaboration agreements rather than product sales.

−1 296,7 %

−1 327,4 %

+11,7 %

5.71

— Caribou Biosciences, Inc.
	%
Genome-editing platform	0% The chRDNA CRISPR-Cas12a platform used to engineer more precise allogeneic cell therapies and other therapeutic applications.
Clinical-stage cell therapy candidates	0% Allogeneic CAR-T product candidates in clinical development for hematologic malignancies, including vispa-cel and CB-011.
Licensing and collaboration revenue	100% Upfront fees, maintenance fees, milestones, R&D reimbursements, and royalties from third-party licensing arrangements.

Caribou does not yet sell commercial products to patients or hospitals; its current revenue comes from licensing and...

Licensing and collaboration partnersprimary
Third parties that license Caribou intellectual property and pay upfront fees, maintenance fees, milestones, R&D funding, or royalties.
Clinical development ecosystemsecondary
CROs, clinical sites, CMOs, and suppliers that support the advancement and manufacturing of vispa-cel and CB-011.
Future oncology treatment providersemerging
Hospitals, cancer centers, and physicians that would prescribe or administer approved CAR-T therapies in hematologic malignancies.
Patients with hematologic malignanciesemerging
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma and multiple myeloma who are the intended beneficiaries of the pipeline.

Caribou is headquartered in the United States and its business is primarily organized around U.S...

•Headquartered in the United States
•Revenue is from licensing/collaboration, not product sales geography
•Clinical development and corporate functions are centered in the U.S.
•Future commercialization would depend on FDA and foreign approvals
•Global capital markets and geopolitics affect financing and operations

Caribou’s strategy is to advance its two clinical-stage allogeneic CAR-T programs while continuing to build value from...

Progress clinical-stage CAR-T programsshort-term

Clinical proof of concept and later-stage data are necessary to create value and support regulatory and partnering opportunities.

Secure non-dilutive and dilutive fundingshort-term

The company has no product sales and must fund ongoing R&D and trials before commercialization.

Expand platform and partnership valuemedium-term

Broader applicability of chRDNA can create additional programs and licensing opportunities beyond the lead assets.

Caribou faces the classic risks of a clinical-stage biotechnology company: long development timelines, uncertain...

critical

Clinical development failure

Lead programs are still in phase 1, so efficacy, safety, or durability issues could prevent advancement or approval.

Scope: vispa-cel and CB-011
Materiality: high

high

Need for additional capital

The company has no product sales and expects to fund operations through equity, debt, collaborations, and licensing, which may not be available on acceptable terms.

Scope: Ongoing R&D, clinical trials, and corporate overhead
Materiality: high

high

Nasdaq delisting risk

The company disclosed non-compliance with the minimum bid price requirement, which could affect liquidity and financing access.

Scope: CRBU common stock
Materiality: high

high

Competitive pressure in genome editing and cell therapy

Larger competitors may have more capital, manufacturing scale, and clinical experience, making it harder to win development and partnering opportunities.

Scope: Platform and pipeline differentiation
Materiality: high

high

Regulatory and manufacturing execution risk

Allogeneic CAR-T products require successful regulatory review, commercial-scale manufacturing, and distribution capabilities before revenue can be generated.

Scope: Future commercialization
Materiality: high

Licensing and collaboration revenue recognition

Can create uneven quarterly revenue and judgment around timing

Research and development expense recognition

Major driver of operating loss volatility

Long-lived asset impairment

Potential non-cash write-downs

Prepaid expenses and deferred R&D payments

Affects timing of expense recognition and period comparability

Caribou Biosciences, Inc.

Clinical development failure

Need for additional capital

Nasdaq delisting risk

Competitive pressure in genome editing and cell therapy

Regulatory and manufacturing execution risk

CRISPR Therapeutics AG

Allogene Therapeutics, Inc.

CRESCENT BIOPHARMA, INC.

CERO THERAPEUTICS HOLDINGS, INC.

PRECISION BIOSCIENCES INC

Beam Therapeutics Inc.